On
CIMERLI solution for injection 0.3 mg (6 mg/mL) and 0.5 mg (10 mg/mL) is an FDA-approved biosimilar to LUCENTIS (ranibizumab) that is indicated for the treatment of multiple retinal diseases including wet age-related macular degeneration (wAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), myopic choroidal neovascularization (mCNV) and diabetic retinopathy (DR). CIMERLI was approved by the FDA on
According to
The post
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Dr. Stephanie Dusaban Gonzales
Suite 4100
CA 90017
Tel: 212813 8800
E-mail: rmertz@goodwinlaw.com
URL: www.goodwinlaw.com
© Mondaq Ltd, 2024 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source